All eyes on Moderna Q1 earnings with focus on pipeline beyond COVID
Maddie Meyer/Getty Images News
Moderna (NASDAQ:MRNA) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.
The consensus EPS Estimate is -$1.74 (-120.3% Y/Y) and the consensus Revenue Estimate is $1.17B (-80.8% Y/Y).
Over the last 2 years, MRNA has beaten EPS estimates 75% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 6 downward. Revenue estimates have seen 2 upward revisions and 3 downward.
The mRNA COVID vaccine maker's stock fell -6.70% on Feb. 23 after mixed Q4 results. EPS declined -68% Y/Y and missed analysts estimates. However, revenue surpassed expectations despite a ~29% Y/Y to $5.08B.

In March, Moderna CEO Stephane Bancel defended the plan to quadruple the price of the COVID-19 vaccine noting that it was fair as the biotech will lose economies of scale after May 11, when government procurement of the shots end. The company plans to price the shot at up to ~$130 per dose in the U.S.
Moderna saw a win in a years-long patent dispute with Arbutus over messenger-RNA-based COVID vaccine technology after a U.S. appeals court sided with company.
Looking beyond the COVID vaccine success, last month, Moderna reported detailed data from the much talked about personalized cancer vaccine mRNA-4157 (V940) in combination with Merck's blockbuster cancer drug Keytruda to treat skin cancer. The combo had helped cut the risk of recurrence or death by 44%.
The vaccine has also gained a Priority Medicines (PRIME) scheme designation in Europe.
However, the company's flu vaccine mRNA-1010 did not have the desired success as the shot showed mixed results in two phase 3 trials â P301 and P302.
Moderna is also undertaking partnerships in an effort to expand its research arena, such as the one with Gandeeva for protein surface structures.
Recent earnings Analysis from our contributors: Moderna Stock: Looking A Little Undervalued Ahead Of Q1 Earnings
More on Moderna: Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19